Lesson plan
LSZ
LSZ, also known as lysergic acid 2,4-dimethylazetidide or as LA-Azetidide (LA-Az), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT 2A receptor. It also interacts with dopamine receptors. The compound is a close analogue of LSD that has been modified at the amide to be more rigid and to have three diastereomers. LA-SS-Az, the (S,S)- isomer, is the most potent and similar isomer to LSD, and is the typically employed form of LSZ. LA-SS-Az and the other isomers of LSZ produce psychedelic-like effects in animals. LSZ was first described in the scientific literature by David E. Nichols and colleagues in 2002. It was developed as a tool for studying psychedelic interactions with the serotonin 5-HT 2A receptor and followed the earlier unstable compound LA-Aziridine developed by Nichols and Robert Oberlender. LSZ, under the name "diazedine", may have been produced on a small scale by the LSD manufacturers William Leonard Pickard and Gordon Todd Skinner around the year 2000. It was first definitely encountered as a novel designer drug in 2013 and then became a popular psychedelic. LSZ is a controlled substance in several European countries.
Article summary
LSZ, also known as lysergic acid 2,4-dimethylazetidide or as LA-Azetidide (LA-Az), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT 2A receptor. It also interacts with dopamine receptors. The compound is a close analogue of LSD that has been modified at the amide to be more rigid and to have three diastereomers. LA-SS-Az, the (S,S)- isomer, is the most potent and similar isomer to LSD, and is the typically employed form of LSZ. LA-SS-Az and the other isomers of LSZ produce psychedelic-like effects in animals. LSZ was first described in the scientific literature by David E. Nichols and colleagues in 2002. It was developed as a tool for studying psychedelic interactions with the serotonin 5-HT 2A receptor and followed the earlier unstable compound LA-Aziridine developed by Nichols and Robert Oberlender. LSZ, under the name "diazedine", may have been produced on a small scale by the LSD manufacturers William Leonard Pickard and Gordon Todd Skinner around the year 2000. It was first definitely encountered as a novel designer drug in 2013 and then became a popular psychedelic. LSZ is a controlled substance in several European countries.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.